Related references
Note: Only part of the references are listed.Competing Risks Model in Screening for Preeclampsia by Serum Placental Growth Factor and Soluble fms-Like Tyrosine Kinase-1 at 30-33 Weeks' Gestation
Jonathan Lai et al.
FETAL DIAGNOSIS AND THERAPY (2014)
Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia
Wenda Ramma et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2014)
Effects of Pravastatin on Angiogenic and Placental Hypoxic Imbalance in a Mouse Model of Preeclampsia
Antonio F. Saad et al.
REPRODUCTIVE SCIENCES (2014)
Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?
L. Myatt et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2013)
Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia A Prospective Multicenter Study
Lucy C. Chappell et al.
CIRCULATION (2013)
Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study
Demetrios Rizos et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2013)
Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation
Akihide Ohkuchi et al.
HYPERTENSION RESEARCH (2013)
Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy
Thomas F. McElrath et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2012)
Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis
C. E. Kleinrouweler et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2012)
Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia
Sarosh Rana et al.
CIRCULATION (2012)
Angiogenic Factors in Superimposed Preeclampsia A Longitudinal Study of Women With Chronic Hypertension During Pregnancy
Uma Perni et al.
HYPERTENSION (2012)
Placental Growth Factor for the Prediction of Adverse Outcomes in Patients with Suspected Preeclampsia or Intrauterine Growth Restriction
Jeanne Sibiude et al.
PLOS ONE (2012)
Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia
Ravi Thadhani et al.
CIRCULATION (2011)
Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia
Tinnakorn Chaiworapongsa et al.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2011)
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks
Ranjit Akolekar et al.
PRENATAL DIAGNOSIS (2011)
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model
Keiichi Kumasawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension
Muna Noori et al.
CIRCULATION (2010)
The perinatal implications of angiogenic factors
Gordon C. S. Smith et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2009)
The Global Impact of Pre-eclampsia and Eclampsia
Lelia Duley
SEMINARS IN PERINATOLOGY (2009)
Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia
Antonio De Vivo et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2008)
First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia
Marc U. Baumann et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast
Carine Munaut et al.
HUMAN REPRODUCTION (2008)
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age
Offer Erez et al.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2008)
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate
Roberto Romero et al.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2008)
Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia
R. Akolekar et al.
ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2008)
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation
M. D. Savvidou et al.
ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2008)
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia
Sarosh Rana et al.
HYPERTENSION (2007)
Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1
Melissa Cudmore et al.
CIRCULATION (2007)
Biology of vascular endothelial growth factors
Himadri Roy et al.
FEBS LETTERS (2006)
Circulating angiogenic factors and the risk of preeclampsia
RJ Levine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Expression and function of placenta growth factor: Implications for abnormal placentation
DS Torry et al.
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION (2003)
Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction
JP Granger et al.
HYPERTENSION (2001)
Share Paper
